BriaCell Therapeutics (TSE:BCT) Stock Price Down 0.1% – Time to Sell?

BriaCell Therapeutics Corp. (TSE:BCT) traded down 0.1% on Friday . The company traded as low as C$9.80 and last traded at C$10.02. 5,862 shares were traded during mid-day trading, a decline of 58% from the average session volume of 13,925 shares. The stock had previously closed at C$10.03.

BriaCell Therapeutics Stock Performance

The company’s 50 day moving average price is C$12.82 and its 200-day moving average price is C$15.43. The company has a market cap of C$18.88 million, a price-to-earnings ratio of -0.30 and a beta of 3.42.

About BriaCell Therapeutics

BriaCell Therapeutics Corp. is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care. Bria-IMT(TM), BriaCell’s lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC). MBC is breast cancer that has spread to other tissues. Bria-IMT(TM) is a targeted cell-based immunotherapy. Additionally, BriaCell is developing, Bria-OTS(TM), a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical study initially targeting breast cancer, with extension to prostate cancer, and other cancers.